Bupropion for the Treatment of Methamphetamine Dependence - 1

National Institute on Drug Abuse (NIDA)150 enrolled

Overview

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

150

Conditions

Amphetamine-Related Disorders

Interventions

BupropionDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis * Subject must be willing to comply with study procedures. * Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures * Be able to comply with protocol requirements Exclusion Criteria: * Please contact site for more information.

Locations (5)

Matrix Institute on Addictions

Costa Mesa, California, United States

South Bay Treatment Center

San Diego, California, United States

Pacific Addiction Research Center

Honolulu, Hawaii, United States

Powell Chemical Dependency Center

Des Moines, Iowa, United States

Outcomes

Primary Outcomes

Severity addiction

Methamphetamine use

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.